Sycamore’s Boots sale could boost Walgreens buyout payday

Sycamore Partners has agreed to sell Boots for about $9 billion, a move that could deepen returns from its Walgreens Boots Alliance takeover while leaving Walgreens with a heavy debt burden. The deal spotlights how the private equity firm financed the buyout and the pressure that high interest costs could place on Walgreens workers and operations.

Why it matters: - Sycamore Partners’ planned sale of Boots could turn its Walgreens Boots Alliance takeover into an even larger profit center. - Walgreens is left with billions in debt at high interest rates, which can squeeze staffing, store operations and future spending. - The structure of the buyout raises questions about whether value is being extracted from assets while the U.S. pharmacy business absorbs the financing burden.

What happened: - Sycamore Partners reached a deal to sell British pharmacy chain Boots for roughly $9 billion. - The sale comes a little more than a year after Sycamore acquired Walgreens Boots Alliance. - Walgreens faces billions of dollars in high-interest debt after the buyout. - The proposed sale could increase returns for Sycamore and other investors in the deal.

The details: - Sycamore Partners Wing Co-Invest, one of the vehicles used to buy Walgreens Boots Alliance, had more than doubled in value to 2.28x as of June 30, according to reports from one investor. - Walgreens said in June 2025 that $13.3 billion, or 71%, of the purchase price would be funded with debt. - Walgreens has as much as $8.57 billion in debt at interest rates as high as 10.67% as of June 30, 2026. - Before the merger, Walgreens said Sycamore had obtained $8.57 billion in debt commitments secured by the company’s U.S. retail pharmacy operations and real estate. - That debt commitment was 23% more than the combined Walgreens Boots Alliance debt load before the acquisition. - If Walgreens drew the full $8.57 billion, every quarter-point increase in rates would add more than $20 million a year in interest expense. - Walgreens has 211,000 employees. - Walgreens has also faced concerns about understaffing since the buyout, alongside store closures and staff reductions.

Between the lines: - The transaction appears to fit a familiar private-equity playbook: buy a struggling retailer, split off valuable assets, and use savings from cost cuts to support investor returns. - The Wall Street Journal described Sycamore’s approach in 2018 as one that often does not depend on turning around the core business. - Jim Baker of the Private Equity Stakeholder Project said Sycamore is already seeing substantial returns from its Walgreens investment and that a Boots sale could make the payoff even bigger. - Baker also said Walgreens workers and customers are likely to bear the consequences of cost cutting.

What’s next: - Sycamore’s Boots sale could close as a major test of how much value remains in the rest of Walgreens Boots Alliance. - Walgreens will likely continue facing pressure from debt service costs as market rates stay elevated. - Any further asset sales or restructuring moves could draw more scrutiny over staffing, store closures and the company’s long-term strategy.

The bottom line: - Boots may be the clearest sign yet that Sycamore’s Walgreens deal is delivering for investors first and leaving Walgreens to manage the debt.